MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
11.12
+2.82
+33.98%
After Hours: 11.11 -0.01 -0.09% 19:59 12/05 EST
OPEN
8.50
PREV CLOSE
8.30
HIGH
11.30
LOW
8.43
VOLUME
4.35M
TURNOVER
--
52 WEEK HIGH
11.30
52 WEEK LOW
2.760
MARKET CAP
1.16B
P/E (TTM)
-2.8849
1D
5D
1M
3M
1Y
5Y
1D
After losing 3.7% in the past year, Alumis Inc. (NASDAQ:ALMS) institutional owners must be relieved by the recent gain
Simply Wall St · 21h ago
Alumis Inc. Director Srinivas Akkaraju Reports Acquisition of Common Shares
Reuters · 1d ago
Alumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones
Reuters · 2d ago
Director Makes Major Investment in Alumis Inc. Stock!
TipRanks · 4d ago
Alumis Inc. Director Srinivas Akkaraju Reports Acquisition of Common Shares
Reuters · 4d ago
Weekly Report: what happened at ALMS last week (1124-1128)?
Weekly Report · 4d ago
Major Stakeholders Show Confidence in Alumis Inc. with Significant Stock Purchases!
TipRanks · 11/26 02:02
Foresite Capital Management VI LLC Acquires Common Shares of Alumis Inc
Reuters · 11/25 21:03
More
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.